Why Is Moderna (MRNA) Stock Rising in Pre-Market Today, 3/4/26?

2026-03-04 14:04:28

Moderna MRNA -5.71% ▼ stock is up by almost 7% in pre-market hours on Wednesday after the vaccine maker announced it had settled patent litigation with Arbutus Biopharma ABUS +0.43% ▲ and Genevant Sciences. Notably, Citi’s five-star-rated analyst Geoff Meacham said the settlement removes a key overhang for MRNA stock, noting that the agreement is not the best-case outcome of an outright legal victory, but it is still better than many investors had feared.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

For context, Moderna is a biotechnology company that develops mRNA-based vaccines and therapeutics, best known for its COVID-19 vaccine.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes